GU Podcast (2020) - Sequencing Of Agents And Combination Of Treatment Options For RCC

At the conclusion of this activity, participants will be able to: 1. Explain the sequencing of novel therapies and be able to identify patient progression of disease. 2. Describe a patient-specific treatment plan that optimizes the use of targeted and immunological agents for the treatment of kidney cancer. This educational series is supported by independent educational grants from: Astellas AstraZeneca Bristol Myers Squibb Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Merck Pfizer, Inc Sanofi Genzyme UroGen Pharma, Inc. CME Available: auau.auanet.org/node/29811